Education
About Us
Working with TipRanks
Follow Us
BriaCell Therapeutics (TSE:BCT)
:BCT
RESEARCH TOOLSreports
Total Valuation
BriaCell Therapeutics has a market cap or net worth of C$32.58M. The enterprise value is C$22.37M.
Market CapC$32.58M
Enterprise ValueC$22.37M
Share Statistics
BriaCell Therapeutics has 5,715,407 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding5,715,407
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
BriaCell Therapeutics’s return on equity (ROE) is 5.38 and return on invested capital (ROIC) is -91.07%.
Return on Equity (ROE)5.38
Return on Assets (ROA)-0.75
Return on Invested Capital (ROIC)-91.07%
Return on Capital Employed (ROCE)-0.92
Revenue Per Employee0.00
Profits Per Employee-1.27M
Employee Count16
Asset Turnover0.00
Inventory Turnover<0.01
Valuation Ratios
The current PE Ratio of BriaCell Therapeutics is -76.62. BriaCell Therapeutics’s PEG ratio is -0.58.
PE Ratio-76.62
PS Ratio0.00
PB Ratio-411.82
Price to Fair Value-411.82
Price to FCF-65.51
Price to Operating Cash Flow-65.51
PEG Ratio-0.58
Income Statement
In the last 12 months, BriaCell Therapeutics had revenue of 0.00 and earned -20.30M in profits. Earnings per share was -1.74.
Revenue0.00
Gross Profit-20.49K
Operating Income-23.27M
Pretax Income-20.30M
Net Income-20.30M
EBITDA-27.22M
Earnings Per Share (EPS)-1.74
Cash Flow
In the last 12 months, operating cash flow was -21.99M and capital expenditures 0.00, giving a free cash flow of -21.99M billion.
Operating Cash Flow-21.99M
Free Cash Flow-21.99M
Free Cash Flow per Share-3.85
Dividends & Yields
BriaCell Therapeutics pays an annual dividend of C$0.09, resulting in a dividend yield of ―
Dividend Per ShareC$0.09
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.64
52-Week Price Change-87.54%
50-Day Moving Average5.83
200-Day Moving Average11.88
Relative Strength Index (RSI)45.19
Average Volume (3m)19.91K
Important Dates
BriaCell Therapeutics upcoming earnings date is Jun 11, 2025, TBA Not Confirmed.
Last Earnings DateMar 12, 2025
Next Earnings DateJun 11, 2025
Ex-Dividend DateSep 05, 2023
Financial Position
BriaCell Therapeutics as a current ratio of 14.96, with Debt / Equity ratio of 0.00%
Current Ratio14.96
Quick Ratio11.81
Debt to Market Cap0.00
Net Debt to EBITDA0.78
Interest Coverage Ratio0.00
Taxes
In the past 12 months, BriaCell Therapeutics has paid -152.62K in taxes.
Income Tax-152.62K
Effective Tax Rate<0.01
Enterprise Valuation
BriaCell Therapeutics EV to EBITDA ratio is -56.36, with an EV/FCF ratio of -64.62.
EV to Sales0.00
EV to EBITDA-56.36
EV to Free Cash Flow-64.62
EV to Operating Cash Flow-64.62
Balance Sheet
BriaCell Therapeutics has C$5.01M in cash and marketable securities with $0.00 in debt, giving a net cash position of -C$5.01M billion.
Cash & Marketable SecuritiesC$5.01M
Total Debt$0.00
Net Cash-C$5.01M
Net Cash Per Share-C$0.88
Tangible Book Value Per Share-C$0.26
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for BriaCell Therapeutics is C$44.14, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetC$44.14
Price Target Upside674.39% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast56.78%